Sohm, Inc. (SHMN) Review: From Expanding Product Portfolio To Corporate Headquarters
Seeking Alpha Analyst Since 2008
Sohm is a pharmaceutical company focused on developing, manufacturing, and distributing generic, brand generic, private label, and in-house innovated pharmaceuticals, cosmeceuticals, and nutraceuticals.
In line with its goal of being a global leader in the improvement of health and quality of human life, Sohm has developed a product portfolio that includes 11 new over-the-counter pharmaceutical products, as well as an expanding cosmeceutical line.
The company's expertise includes a wide range of drug delivery technologies, including solid dosage form, oral-controlled and sustained release semi-solid, liquid, oral transmucosal, transdermal, gel, injectable, and others.
The R&D and subsequent manufacture of these produces is conducted in the company's global R&D facilities, which adhere to all applicable regulatory requirements to the highest degree. The company's commitment is to ensure that this high standard is maintained by all employees at all levels of the corporation by continuous assessment and monitoring of the output of the existing quality systems. Management also applies the latest industry guidelines and regulations, including all WHO-CGMP and USFDA guidelines.
Sohm is headquartered in Buena Park, Calif., with international headquarters in Ahmedabad, India, and several corporate offices located within the UK and China.
For more information, visit sohm.com
QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.